Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. / Wandall-Holm, Malthe Faurschou; Buron, Mathias Due; Kopp, Tine Iskov; Thielen, Karsten; Sellebjerg, Finn; Magyari, Melinda.

In: Journal of Neurology, Neurosurgery and Psychiatry, Vol. 93, No. 8, 2022, p. 858-864.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Wandall-Holm, MF, Buron, MD, Kopp, TI, Thielen, K, Sellebjerg, F & Magyari, M 2022, 'Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis', Journal of Neurology, Neurosurgery and Psychiatry, vol. 93, no. 8, pp. 858-864. https://doi.org/10.1136/jnnp-2022-329058

APA

Wandall-Holm, M. F., Buron, M. D., Kopp, T. I., Thielen, K., Sellebjerg, F., & Magyari, M. (2022). Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 93(8), 858-864. https://doi.org/10.1136/jnnp-2022-329058

Vancouver

Wandall-Holm MF, Buron MD, Kopp TI, Thielen K, Sellebjerg F, Magyari M. Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. 2022;93(8):858-864. https://doi.org/10.1136/jnnp-2022-329058

Author

Wandall-Holm, Malthe Faurschou ; Buron, Mathias Due ; Kopp, Tine Iskov ; Thielen, Karsten ; Sellebjerg, Finn ; Magyari, Melinda. / Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis. In: Journal of Neurology, Neurosurgery and Psychiatry. 2022 ; Vol. 93, No. 8. pp. 858-864.

Bibtex

@article{57639936ad1a4188bafbe4862329aa35,
title = "Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis",
abstract = "Background Initiation of disease-modifying therapy early in the disease course of relapsing-remitting multiple sclerosis (RRMS) has demonstrated beneficial effects on clinical outcomes, but socioeconomic outcomes remain largely unexplored. Objective To investigate the association between the delay from disease onset to first treatment and the hazard of disability pension. Methods We performed a population-based cohort study with data from the nationwide Danish Multiple Sclerosis Registry and Danish nationwide registries. Patients with a disease onset between 1 January 1996 to 5 April 2016 were followed until disability pension or a competing risk/censoring event. 7859 patients were assessed for eligibility of which 5208 were included in the final cohort. Key inclusion criteria were: a diagnosis of multiple sclerosis, relapsing-remitting phenotype, treatment in history, age 18-65 years and an Expanded Disability Status Scale≤4. Patients were categorised according to time from onset to first treatment: within 1 year (early), between 1 and 4 years (intermediate) and from 4 to 8 years (late). Results Of the 5208 patients, 1922 were early, 2126 were intermediate and 1160 were late. Baseline clinical and socioeconomic variables were well balanced. The hazard of receiving disability pension increased with increasing delay of treatment initiation compared with the early group. Cox regression estimates adjusted for clinical and socioeconomic confounders: intermediate (HR, 1.37; 95% CI, 1.12 to 1.68) and late (HR, 1.97; 95% CI, 1.55 to 2.51). Conclusion Early treatment initiation is associated with a reduced risk of disability pension in patients with RRMS. This finding underlines the importance of early diagnosis and treatment on a patient-centred, socioeconomic disability milestone. ",
keywords = "EPIDEMIOLOGY, MULTIPLE SCLEROSIS",
author = "Wandall-Holm, {Malthe Faurschou} and Buron, {Mathias Due} and Kopp, {Tine Iskov} and Karsten Thielen and Finn Sellebjerg and Melinda Magyari",
note = "Publisher Copyright: {\textcopyright} ",
year = "2022",
doi = "10.1136/jnnp-2022-329058",
language = "English",
volume = "93",
pages = "858--864",
journal = "Journal of Neurology, Neurosurgery and Psychiatry",
issn = "0022-3050",
publisher = "B M J Group",
number = "8",

}

RIS

TY - JOUR

T1 - Time to first treatment and risk of disability pension in relapsing-remitting multiple sclerosis

AU - Wandall-Holm, Malthe Faurschou

AU - Buron, Mathias Due

AU - Kopp, Tine Iskov

AU - Thielen, Karsten

AU - Sellebjerg, Finn

AU - Magyari, Melinda

N1 - Publisher Copyright: ©

PY - 2022

Y1 - 2022

N2 - Background Initiation of disease-modifying therapy early in the disease course of relapsing-remitting multiple sclerosis (RRMS) has demonstrated beneficial effects on clinical outcomes, but socioeconomic outcomes remain largely unexplored. Objective To investigate the association between the delay from disease onset to first treatment and the hazard of disability pension. Methods We performed a population-based cohort study with data from the nationwide Danish Multiple Sclerosis Registry and Danish nationwide registries. Patients with a disease onset between 1 January 1996 to 5 April 2016 were followed until disability pension or a competing risk/censoring event. 7859 patients were assessed for eligibility of which 5208 were included in the final cohort. Key inclusion criteria were: a diagnosis of multiple sclerosis, relapsing-remitting phenotype, treatment in history, age 18-65 years and an Expanded Disability Status Scale≤4. Patients were categorised according to time from onset to first treatment: within 1 year (early), between 1 and 4 years (intermediate) and from 4 to 8 years (late). Results Of the 5208 patients, 1922 were early, 2126 were intermediate and 1160 were late. Baseline clinical and socioeconomic variables were well balanced. The hazard of receiving disability pension increased with increasing delay of treatment initiation compared with the early group. Cox regression estimates adjusted for clinical and socioeconomic confounders: intermediate (HR, 1.37; 95% CI, 1.12 to 1.68) and late (HR, 1.97; 95% CI, 1.55 to 2.51). Conclusion Early treatment initiation is associated with a reduced risk of disability pension in patients with RRMS. This finding underlines the importance of early diagnosis and treatment on a patient-centred, socioeconomic disability milestone.

AB - Background Initiation of disease-modifying therapy early in the disease course of relapsing-remitting multiple sclerosis (RRMS) has demonstrated beneficial effects on clinical outcomes, but socioeconomic outcomes remain largely unexplored. Objective To investigate the association between the delay from disease onset to first treatment and the hazard of disability pension. Methods We performed a population-based cohort study with data from the nationwide Danish Multiple Sclerosis Registry and Danish nationwide registries. Patients with a disease onset between 1 January 1996 to 5 April 2016 were followed until disability pension or a competing risk/censoring event. 7859 patients were assessed for eligibility of which 5208 were included in the final cohort. Key inclusion criteria were: a diagnosis of multiple sclerosis, relapsing-remitting phenotype, treatment in history, age 18-65 years and an Expanded Disability Status Scale≤4. Patients were categorised according to time from onset to first treatment: within 1 year (early), between 1 and 4 years (intermediate) and from 4 to 8 years (late). Results Of the 5208 patients, 1922 were early, 2126 were intermediate and 1160 were late. Baseline clinical and socioeconomic variables were well balanced. The hazard of receiving disability pension increased with increasing delay of treatment initiation compared with the early group. Cox regression estimates adjusted for clinical and socioeconomic confounders: intermediate (HR, 1.37; 95% CI, 1.12 to 1.68) and late (HR, 1.97; 95% CI, 1.55 to 2.51). Conclusion Early treatment initiation is associated with a reduced risk of disability pension in patients with RRMS. This finding underlines the importance of early diagnosis and treatment on a patient-centred, socioeconomic disability milestone.

KW - EPIDEMIOLOGY

KW - MULTIPLE SCLEROSIS

U2 - 10.1136/jnnp-2022-329058

DO - 10.1136/jnnp-2022-329058

M3 - Journal article

C2 - 35688630

AN - SCOPUS:85132201846

VL - 93

SP - 858

EP - 864

JO - Journal of Neurology, Neurosurgery and Psychiatry

JF - Journal of Neurology, Neurosurgery and Psychiatry

SN - 0022-3050

IS - 8

ER -

ID: 329613409